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Abstract
Due to relatively high costs and labor required for experimental profiling of the full target
space of chemical compounds, various machine learning models have been proposed as
cost-effective means to advance this process in terms of predicting the most potent com-
pound-target interactions for subsequent verification. However, most of the model predic-
tions lack direct experimental validation in the laboratory, making their practical benefits
for drug discovery or repurposing applications largely unknown. Here, we therefore intro-
duce and carefully test a systematic computational-experimental framework for the pre-
diction and pre-clinical verification of drug-target interactions using a well-established
kernel-based regression algorithm as the prediction model. To evaluate its performance,
we first predicted unmeasured binding affinities in a large-scale kinase inhibitor profiling
study, and then experimentally tested 100 compound-kinase pairs. The relatively high
correlation of 0.77 (p < 0.0001) between the predicted and measured bioactivities sup-
ports the potential of the model for filling the experimental gaps in existing compound-tar-
get interaction maps. Further, we subjected the model to a more challenging task of
predicting target interactions for such a new candidate drug compound that lacks prior
binding profile information. As a specific case study, we used tivozanib, an investigational
VEGF receptor inhibitor with currently unknown off-target profile. Among 7 kinases with
high predicted affinity, we experimentally validated 4 new off-targets of tivozanib, namely
the Src-family kinases FRK and FYN A, the non-receptor tyrosine kinase ABL1, and the
serine/threonine kinase SLK. Our sub-sequent experimental validation protocol effec-
tively avoids any possible information leakage between the training and validation data,
and therefore enables rigorous model validation for practical applications. These results
demonstrate that the kernel-based modeling approach offers practical benefits for prob-
ing novel insights into the mode of action of investigational compounds, and for the identi-
fication of new target selectivities for drug repurposing applications.
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Author summary
Significant efforts have been devoted in recent years to the development of machine learn-
ing models to support different stages of drug development process. Given the enormous
size of the chemical universe, such models could offer a complementary and cost-effective
means to experimental determination of drug-target interactions, toward prioritization of
the most potent ones for further verification in the laboratory. In order to demonstrate
the benefits of the prediction models in practical application cases, we carefully evaluated
the predictive power of a well-established machine learning model in filling the gaps in
existing profiling studies and prediction of target interactions for a new drug candidate.
As a specific case study, we focused on kinase inhibitors, which form the largest class of
new drugs approved for cancer treatment, but are also known to have wide multi-target
activities contributing both to their therapeutic and toxic responses. The high agreement
observed between the predicted and experimentally-measured drug-target bioactivities
under the implemented rigorous validation setup demonstrates the potential of the
machine learning approach, not only for filling the gaps in existing drug-target interaction
maps, but also toward off-target interaction prediction for investigational drugs, and find-
ing potential new uses for already approved drugs (drug repurposing).
Introduction
Deregulated kinase activity plays a role in many diseases, hence calling for therapeutic com-
pounds that could effectively inhibit specific members of the protein kinome. Although kinase
inhibitors form the largest group of new drugs approved for cancer treatment [1], a majority
of them are ATP-competitive, and therefore present a highly promiscuous mechanism of
action (MoA), due to the high evolutionary conservation of the kinase ATP-binding pockets
[2,3]. The polypharmacological interactions contribute both to therapeutic and toxic responses
seen in clinically-approved and investigational kinase inhibitors. Thus, improved knowledge
of the complex compound-target binding interactions across the full protein kinome, includ-
ing both on- and off-target effects, is of high clinical relevance for future drug discovery
applications.
Recent technological advances in chemoproteomic approaches, such as thermal profiling
[4], have enabled efficient determination of kinome-wide compound potency. Several com-
mercial providers are available for preclinical kinase inhibitor testing in vitro, including Disco-
verX, Millipore and Reaction Biology. Even though the experimental compound-target
interaction mapping is critical to characterizing a compound’s MoA, computational methods
provide a complementary and cost-effective approach with the potential to accelerate the
exploration of the enormous size of the chemical universe, estimated to consist of approxi-
mately 1020 molecules exhibiting good pharmacological properties [5]. The hypothesis is that
in silico models could provide fast, large-scale and systematic pre-screening of chemical
probes, toward prioritization of the most potent interactions for further in vitro or ex vivo veri-
fication in the laboratory [6–10].
In particular, a lot of work has been devoted to compound-based interaction prediction
methods, including quantitative structure-activity relationship (QSAR) models, which aim to
relate structural properties of the chemical molecules to their bioactivity profiles [11,12].
Another class of machine learning methods, so called target-based methods, focus on evaluat-
ing similarities between amino acid sequences or three-dimensional structures of protein
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targets [13]. In these supervised learning approaches, models are trained using available bioac-
tivity data, together with either compound or protein information, which allows then predict-
ing either new target interactions for a given drug or new drugs targeting a given protein.
Furthermore, such methods typically focus on a limited set of molecules of interest.
As a more recent class of computational modelling approaches, systems-based frameworks
take advantage of the information available on both compounds and targets. For instance,
Yamanishi et al. proposed a supervised machine learning approach for categorizing drug-tar-
get pairs as interacting or non-interacting based on an integrated model of chemical and geno-
mic molecular profiles [14]. Since this seminal work, a wide variety of systems-based
prediction methods have been developed that utilize various molecular descriptors and learn-
ing techniques, including random forest, neural networks and kernel learning [15–32]. Even
though such models may hold a great potential, their computational predictions are rarely
being directly verified in the laboratory and, consequently, their practical benefits for the drug
discovery or repurposing applications remain largely unknown.
Toward testing the practical potential of systems-based machine learning models, we imple-
mented a computational-experimental framework for prediction and verification of com-
pound-target bioactivity profiles (Fig 1). We focused on a regression problem, where the task
is to predict the actual binding affinities, instead of the standard bioactivity classification set-
ting that treats molecular interactions as simple on/off relationships. As a prediction model,
we applied a well-established kernel-based regularized least squares learning algorithm
(KronRLS [33]), because kernels, in addition to offering a computationally efficient means for
increasing the power of linear learning algorithms, are particularly well-suited for capturing
and learning complex molecular properties for prediction purposes [34,35].
Fig 1. An overview of our computational-experimental framework for prediction and pre-clinical testing of compound-protein bioactivity
profiles. Two separate prediction problems are considered: (1) filling the gaps in existing compound-target interaction maps and (2) prediction of target
interactions for a new or investigational compound. Molecular descriptors of drug compounds and protein targets are encoded as kernels, and used for
binding affinity prediction with a regularized least squares regression model KronRLS. Finally, a subset of predicted compound-protein bioactivities is
experimentally tested (see Materials and Methods for details). Since the experimental validations do not exists at the time of making the predictions, this
approach effectively assesses any potential model overfitting to the training data only. We chose to use kernel-based models as these are well-suited for
representing structured objects, such as molecules, that cannot be accurately described by a standard feature vector. Different types of drug and protein
kernels can be calculated using readily available chemical structures and amino acid sequences. The resulting matrices associate all pairs of input objects,
and therefore a kernel function can be considered as a similarity measure.
https://doi.org/10.1371/journal.pcbi.1005678.g001
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The specific contributions of the work are the following. First, we evaluated a large number
of molecular descriptors in the form of kernels, including our novel, extended target profile-
based protein kernel, and a generic string kernel that has not previously been used in the con-
text of compound-protein interaction prediction. Second, we show how these kernels guided
us in filling the gaps in a large-scale compound-kinase interaction map [3]. Third, we experi-
mentally tested a subset of 100 predicted binding affinities, achieving a high correlation of 0.77
between the measured and predicted bioactivities. Finally, we demonstrate the potential of the
modelling approach in a more challenging task of predicting target selectivities for such a new
candidate compound that has no bioactivity data available for model training. As a specific
case study, we used an investigational tyrosine kinase inhibitor tivozanib whose established
target profile consists only of 3 on-targets. We experimentally tested and validated 4 out of 7
kinases predicted as tivozanib’s off-targets, providing novel insights into its MoA, and thereby
extending the potential therapeutic target space of tivozanib.
Results
In the real use cases, the problem of compound-protein interaction prediction should be con-
sidered separately under four different scenarios, depending on whether or not the training
and test sets share common compounds, proteins, or both (Fig 2 and S1 Table). In the below
results sections, we focused on the two most common and practical scenarios of (1) filling the
experimental gaps in compound-target profiling datasets (referred to as the Bioactivity Imputa-
tion scenario, Fig 2A) and (2) prediction of target interactions for an investigational drug com-
pound (referred to as the New Drug scenario, Fig 2B). Moreover, S7 Fig shows, for
comparison, the results obtained under the symmetric New Target scenario (Fig 2C).
Evaluation of molecular descriptors for compound-target interaction
inference
A key assumption in the systems-based compound-target interaction prediction algorithm is
that similar drug compounds are likely to bind to similar protein targets, and therefore the
first challenge lies in the representation and use of molecular similarities in the most predictive
way. We encoded here similarities between drugs and similarities between proteins using dif-
ferent types of kernels, constructed based on chemical two- and three-dimensional structures,
amino acid sequences, protein structures, and molecular interaction profiles (see Materials
and Methods for details). Such systematic construction of chemical and genomic molecular
descriptors resulted in 12 drug kernels and 8 protein kernels. To predict compound-protein
binding affinities using the regression setup, we applied a regularized least squares (RLS)
model for each pair of drug kernel and protein kernel (KronRLS algorithm, see Materials and
Methods).
For computational evaluation of the predictive performance of various molecular descrip-
tors and optimization of model parameters under separate prediction scenarios, we carried
out two systematic nested cross-validation (CV) procedures, i.e., leave-one-out cross-valida-
tion (LOO-CV, S12 Fig) and leave-drug-out cross-validation (LDO-CV, S13 Fig), using 16,265
known binding affinities (pKi values) between 152 kinase inhibitors and 138 protein kinases
measured in a large-scale functional bioassay by Metz et al. [3] (S9 Fig). We applied LOO-CV
to tune model parameters and to evaluate its predictive performance when filling experimental
gaps in large-scale target profiling studies (the Bioactivity Imputation scenario, Fig 2A), and
LDO-CV in the inference of target interactions for a new candidate drug compound (theNew
Drug scenario, Fig 2B). LOO-CV corresponds to the design where scattered missing values are
present in otherwise known compound-protein bioactivity matrix, and the aim is to predict
Computational-experimental approach to drug-target interaction mapping
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005678 August 7, 2017 4 / 28
the missing entries within the training data. LDO-CV, on the other hand, simulates more chal-
lenging inference problem, in which the aim is to predict targets of an investigational drug
compound, not encountered in the training data (Materials and Methods, Tables 1 and S1).
Bioactivity Imputation: Computational evaluation of filling in the experimental gaps.
In the first task of filling the gaps in experimental bioactivity profiling study, the Gaussian
Fig 2. Drug-protein interaction prediction scenarios. (dx, px) denotes a query drug-protein pair, the binding
affinity of which is to be predicted. (a) The Bioactivity Imputation scenario: both the drug dx and protein px are
present in the training set, i.e., there exist known bioactivity values for the drug dx and protein px, but not for their
interaction (dx, px). (b) The New Drug scenario: the protein px is present in the training set, whereas the drug dx is
not, i.e., there exist known bioactivity values for the protein px but not for the drug dx. (c) The New Target scenario:
the drug dx is present in the training set, whereas the protein px is not, i.e., there exist known bioactivity values for the
drug dx, but not for the protein px. (d) The New Drug-Target Pair scenario: neither the drug dx nor protein px is
present in the training set, i.e., there exist no bioactivity values neither for the drug dx nor protein px. In this work, we
focused primarily on two most common and practical prediction scenarios of (a) and (b), which correspond to filling
the gaps in existing experimentally-measured drug-target interaction maps and prediction of target interactions for
an investigational drug compound, respectively.
https://doi.org/10.1371/journal.pcbi.1005678.g002
Table 1. Applied nested cross-validation strategies.
LOO-CV LDO-CVa
Aim To evaluate the performance




(the Bioactivity Imputation scenario, Fig 2A).
To evaluate the performance
of the prediction model in the task of predicting
target interactions
for a new candidate drug compound (the New
Drug scenario, Fig 2B).
Outer
CV
One entry (compound-protein pair)
at a time is removed from the
compound-protein interaction matrix Y, and
kept as a test fold.
One row (compound)
at a time is removed from the
compound-protein interaction matrix Y, and
kept as a test fold.
Inner
CV
One entry (compound-protein pair)
at a time is removed from
the remaining part of the compound-protein
interaction matrix Y, and kept as a test fold.
Five rows (compounds) at a time are removed
at random from
the remaining part of the compound-protein
interaction matrix Y, and kept as a test fold.
a In case of LDO-CV, the rows and columns corresponding to the compounds included in the test fold are
removed from the drug kernel matrix KD before model training.
https://doi.org/10.1371/journal.pcbi.1005678.t001
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interaction profile drug kernel (KD-GIP) clearly outperformed other compound descriptors
(Fig 3A and S1 Fig). This is because, in some cases, even a minor structural difference between
chemical molecules causes a striking change in their potency, and such kernel is able to capture
this behavior. Among structural fingerprint-based drug kernels, the ones constructed by com-
parison of two-dimensional substructures defined by PubChem (KD-PubChem-2D) as well as
shortest paths between atoms (KD-sp) yielded the best binding affinity predictions. In case of
both compounds and proteins, the use of three-dimensional conformations (KD-PubChem-
3D, KP-3D-sid, KP-3D-energy) did not lead to improved prediction results.
Among the protein kernels, the protein interaction profile kernel (KP-GIP) and the kernel
based on extended target profile built upon Smith-Waterman amino acid sequence compari-
sons (KP-SW+) showed the best overall performance (Fig 3A). Moreover, KP-SW+, paired
with any drug kernel, achieved higher predictive accuracy than its commonly used counterpart
KP-SW, which is also based on the Smith-Waterman amino acid sequence alignments but of
only proteins included in the training data set, whereas KP-SW+ kernel is calculated based on
more comprehensive, global features (see Materials and Methods for details). Notably, generic
string kernel worked better with kinase domains (KP-GS-domain) and ATP-binding pockets
(KP-GS-atp), compared to full amino acid sequences (KP-GS), indicating their potential for
compound-target interaction inference.
Taken together these computational evaluation results under the Bioactivity Imputation sce-
nario, the best chemical and genomic molecular descriptor pair in filling the gaps in experi-
mental kinase inhibitor target profiling study was formed by KD-GIP and KP-GS-domain
kernels, followed closely by KD-GIP and KP-SW+ kernels, which resulted in high Pearson cor-
relations between the original and predicted compound-kinase binding affinities of 0.829 and
0.828, respectively (p< 0.0001, S2 Fig).
New Drug: Computational evaluation of predicting target interactions for new com-
pounds. Predicting bioactivity signatures for a new drug candidate is a lot more challenging
task, since such chemical probe has no target interaction data available for the model training.
To simulate this setup, we next performed LDO-CV using different pairs of chemical and
genomic molecular descriptors, but without including interaction profile kernels. Among drug
kernels, the one computed using the shortest paths between atoms (KD-sp) demonstrated the
best overall performance (Fig 3B). Together with amino acid sequence-based generic string
protein kernel (KP-GS), it formed the most powerful molecular descriptor pair in the inference
of interactions for an investigational drug candidate, achieving Pearson correlation of 0.653
(p< 0.0001, S2 Fig). We note that a very similar predictive performance was achieved by KD-
sp drug kernel coupled either with KP-GS-atp or KP-GS-domain protein kernels (Pearson cor-
relations of 0.651 and 0.649, respectively).
These computational evaluation results demonstrate that an optimal choice of both drug
and protein kernels depends on the practical application use case, such as whether one is inter-
ested in the Bioactivity Imputation or New Drug prediction scenarios. Computational CV pro-
tocols provided us useful tools for optimizing the prediction models, which is a critical
prerequisite for the achievement of high-quality binding affinity predictions, before going into
the more laborious and expensive experimental validations.
Filling the experimental gaps in large-scale kinase inhibitor target
profiling study
Next, we trained the KronRLS algorithm with 16,265 bioactivities between 152 kinase inhibi-
tors and 138 kinases measured in the study by Metz et al. [3], together with the best-perform-
ing under the Bioactivity Imputation scenario drug interaction profile kernel (KD-GIP) and
Computational-experimental approach to drug-target interaction mapping
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1005678 August 7, 2017 6 / 28
Fig 3. Computational evaluation of the model predictions. (a) Leave-one-out and (b) leave-drug-out cross-validation results. The prediction
accuracy was evaluated with Pearson correlation (r) between binding affinities (pKi) from the study by Metz et al. [3] and those predicted using
KronRLS algorithm with different pairs of compound (rows) and protein (columns) molecular descriptors encoded as kernel matrices (c). The
corresponding root mean squared error (RMSE) values are shown in S1 Fig. Of note, Gaussian interaction profile drug kernel (KD-GIP), which
resulted in the highest predictive performance under the Bioactivity Imputation scenario (a), was not evaluated under the New Drug scenario (b),
Computational-experimental approach to drug-target interaction mapping
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kinase domain-based generic string protein kernel (KP-GS-domain). We then used the opti-
mized model to predict the remaining 4,711 binding affinities that were missing in this experi-
mentally-measured compound-kinase interaction map (S9 Fig).
To assess the model’s practical utility, we experimentally tested a set of 100 predicted bind-
ing affinities between 5 drug compounds (cediranib, lapatinib, gefitinib, pazopanib and vx-
745) and 20 kinases (ABL1,AXL, BRK, BTK, EGFR, FAK, FYN A,HER2,HER4, IGF1R, InsR,
ITK, JAK3, KDR, LCK, LYN B, PYK2, SRC, SYK, TRKA). Among these, new potential interac-
tions, not present in the Metz et al. dataset, were predicted for cediranib, lapatinib and gefitinib
(S4 Fig). We note that pazopanib presented very high prediction accuracy, despite of having a
sparse binding affinity profile available for the model training. On the other hand, vx-745 had
no potent activities, either measured or predicted, against any of the kinases, and therefore it
served as a negative control in the validation (S4 Fig). We tested the predicted bioactivities
using a cell-free ADP-Glo Kinase Assay (see Materials and Methods for details).
We observed a relatively high Pearson correlation of 0.774 (p< 0.0001) between the
model-predicted (pKi) and experimentally-measured (pIC50) bioactivities among the 100 com-
pound-kinase pairs (Fig 4A). The IC50 readout from our assay, similarly to the inhibition con-
stant Ki in the Metz et al. study, indicates the concentration of the compound needed to
inhibit enzymatic activity of a kinase by 50%. Even though IC50 is known to depend on the
concentration of the enzyme, inhibitor, and substrate, along with other experimental condi-
tions, whereas Ki is an intrinsic, thermodynamic quantity independent of the substrate [36],
recent studies have shown a sufficiently high level of association between pIC50 and pKi read-
outs, permitting their reliable comparison [37,38]. We also observed a strong technical correla-
tion of 0.769 (p< 0.0001) between pIC50 readouts from our profiling assay and pKi values
measured in the study by Metz et al. (S5 Fig), which supports the feasibility of our experimen-
tal validations. Furthermore, based on the published information [39], the ATP concentration
used in our assay (10 μM) is expected to be below, or in some cases equal to, the ATP Km val-
ues of the kinases tested, suggesting that the IC50 values should be very close to the respective
Ki values.
We also compared both the model-predicted and experimentally-measured interaction
mapping to the results from another large-scale binding assay by Davis et al [40]. In this study,
72 clinically relevant kinase inhibitors were profiled against 442 kinases, providing, for each
compound-kinase pair tested, dissociation constant Kd, indicating the tendency of a larger
molecular complex to dissociate reversibly into the component molecules. We again observed
a very good agreement (correlation of 0.796, p< 0.0001) between the computationally-pre-
dicted (pKi) and measured (pKd) binding affinities across the overlapping 95 compound-
kinase pairs (S5 Fig). We noted even a higher technical correlation of 0.916 (p < 0.0001)
between pKd values from Davis et al. study and pIC50 values from our experimental assay (S5
Fig). Notably, a comparison between predicted pKi values and measured pKd readouts across a
larger set of 2,662 compound-kinase pairs overlapping between Metz et al. [3] and Davis et al.
[40] studies resulted in a lower correlation (0.642, p< 0.0001, S6 Fig), compared to that when
considering only the pairs included in our experimental assay (0.796, p< 0.0001, S5 Fig). A
high pKd indicates that a substrate is more likely to be bound to an enzyme, whereas pKi mea-
sures the potency of a drug. Even though both high pKi and pKd values are considered as indi-
cators of drug activity, a drug with high pKi does not necessarily result in a high pKd (S6 Fig).
because it is constructed based on the bioactivity profile of a drug to be predicted, that is, using information that in practice is unavailable when
predicting target interactions for a new investigational drug compound.
https://doi.org/10.1371/journal.pcbi.1005678.g003
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As expected, the correlation between the model-predicted and measured by Metz et al. pKi
values in the training data (excluding pairs blinded in the model training, marked with an
orange cross points in Fig 4A) was somewhat higher than that for the missing compound-
kinase pairs (correlation of 0.802, p< 0.0001, S5 Fig). Of note, our experimental assay con-
firmed computationally-predicted high binding affinities between cediranib-KDR, lapatinib-
EGFR and pazopanib-KDR, the two first of which were even not measured in the study of
Metz et al. Further, although some bioactivities missing in Metz et al. dataset corresponded to
compound-kinase pairs already tested in other studies (e.g. lapatinib-EGFRmeasured in the
assay by Davis et al.), these were not used in the training of our model. Taken together, the
observed high agreement between the predicted and experimentally-measured bioactivities
demonstrates the potential of the kernel-based modeling framework with appropriately chosen
kernels for filling the gaps in existing compound-target interaction maps.
Prediction of off-target interactions for an investigational kinase inhibitor
tivozanib
Finally, we tested whether the optimized model can also predict target interactions for a new
chemical probe, which has no profiling data available for the model training. We used here
tivozanib as an example of an investigational tyrosine kinase inhibitor, known to be potent
towards all three VEGF receptors (FLT1, KDR, FLT4) [41]. Beyond VEGFRs, however, the
Fig 4. Comparison between computationally-predicted and experimentally-measured bioactivities. (a) Scatter plot between bioactivity values of
100 compound-kinase pairs (detailed in S2 Table). r indicates Pearson correlation. The orange cross points correspond to compound-kinase pairs tested in
the study of Metz et al. but randomly blinded by us in the training of the model, forming an additional validation set. When no clear interaction between
compound and kinase was observed in our experimental assay, the pIC50 value was set to 4.9 M, corresponding to the highest drug concentration used in
our screen (12,500 nM). The higher the pKi/pIC50 value, the stronger the affinity between the two molecules. Red lines mark a relatively stringent interaction
threshold (7 M), distinguishing the top left corner as the region containing false positive interaction predictions, and the bottom right corner as false negative
predictions. (b) A set of receiver operating characteristic (ROC) curves to investigate the model performance as a function of varying activity threshold. We
applied 11 different interaction threshold values from the pIC50 interval [6 M, 8 M] to binarize the experimentally-measured bioactivities into true class labels,
and then determined how accurately the model can discriminate between the interacting and non-interacting compound-kinase pairs. The average area
under the ROC curves (AUC) equals 0.970.
https://doi.org/10.1371/journal.pcbi.1005678.g004
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target profile of tivozanib has otherwise remained poorly characterized, including its potential
off-targets. We therefore again used 16,265 binding affinities between 152 compounds and 138
kinases measured in the study by Metz et al. to train the KronRLS model with shortest paths
between atoms-based drug kernel (KD-sp) and amino acid sequence-based generic string pro-
tein kernel (KP-GS), which were found to perform best under the New Drug scenario. Since
the model should always be tuned separately under distinct prediction scenarios, even if the
training dataset is the same, the model used here and the one described in the previous section
differ in their chosen kernels and optimized value of the regularization parameter. With the
optimized model, we predicted the bioactivity of tivozanib against the set of 138 kinases (S3
Table).
As the first positive control, the model correctly predicted high potency of tivozanib against
its known on-targets FLT1, KDR and FLT4 (Fig 5A and S3 Table). To further assess the quality
of the predictions, we used publicly available bioactivity data from the study of Gao et al. who
profiled 158 kinase inhibitors, including tivozanib, for their inhibitory activity at 1 μM and
10 μM against 234 kinases [42]. Although the concentrations adopted in this screen were too
high for pre-clinical testing of positive interactions, we used these data to evaluate the negative
predictions from the model. In total, 64 out of 82 kinases with low predicted affinities (pKi < 6
M) were screened by Gao et al. Among these, 59 kinases (92%) have at least 50% of the activity
remaining at the high compound concentration of 1 μM (S3 Table), thus effectively validating
the model’s negative predictions (Fig 5B).
Fig 5. Prediction of target interactions for an investigational kinase inhibitor tivozanib. (a) Predicted and measured bioactivity profiles of tivozanib
against its 3 established on-targets (FLT1, FLT4, KDR; average bioactivity from ChEMBL; S3 Table) and 7 predicted off-target kinases tested in our
experimental assay. Pearson correlation r = 0.668 (p = 0.035). When no clear compound-kinase interaction was observed in our assay, the pIC50 value was
set to 4.9 M, corresponding to the highest drug concentration used (12,500 nM). Predicted values belong to approximately constant range because we
focused on experimental validation of the model-predicted off-target interactions. Three of them turned out to be false positives, and therefore the range of
experimental results varies more than the range of predicted values. (b) Evaluation of negative interaction predictions from the model. Among 82 kinases with
low predicted binding affinities (pKi < 6 M), 64 were screened by Gao et al., and 59 of these are not likely targets of tivozanib (as they have at least 50% of the
activity remaining at the high compound concentration of 1 μM).
https://doi.org/10.1371/journal.pcbi.1005678.g005
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We next went on and tested experimentally 7 predicted off-target interactions (ABL1,
Aurora A, FRK, FYNA,HIPK4, RPS6KB1, SLK). These 7 kinases were selected among the set
of 25 kinases with the highest predicted binding affinities by focusing on off-targets unique to
tivozanib. Specifically, we compared the predicted target interaction profile of tivozanib to
other VEGFR inhibitors found in the ChEMBL database [43]. For instance, RETwas not
selected, even though it was predicted to have high potency towards tivozanib (pIC50 = 6.9 M),
since it is targeted by 76% of VEGFR inhibitors in ChEMBL (potency of at most 100 nM),
whereas FYN A was included in our experimental assay because it is targeted only by 26% of
VEGFR inhibitors (S3 Table). We tested the predicted bioactivities using a cell-free ADP-Glo
Kinase Assay (see Materials and Methods for details).
Among the pre-selected off-target predictions, our experiments confirmed strong binding
affinity between tivozanib and 4 out of the 7 tested kinases (57%), namely FRK,ABL1, SLK and
FYNA (Fig 5A). Statistical significance of this success rate depends on the underlying distribu-
tion of the true target space of tivozanib, which is unknown. However, if one assumes that no
more than 18 of 138 considered kinases are actual targets of tivozanib (13%), then the observed
overlap is significant (p< 0.05, hypergeometric distribution). The observed correlation of
0.668 (p = 0.035, Fig 5A) between the predicted and measured binding affinities can be consid-
ered relatively high, given the rather limited spectrum of kinases tested and the fact that instead
of selecting the top predicted off-targets only, we focused on the set of kinases that were unique
to tivozanib among 25 kinases with the highest predicted binding affinities against it. Our
experimental results provide not only novel insights into the MoA of tivozanib, but also dem-
onstrate how the in silico framework offers a cost-effective tool for prioritizing the most prom-
ising target interactions of an investigational compound for further experimental evaluation.
Discussion
Recently, a lot of effort has been placed on the development of systems-based machine learning
models that could aid drug discovery process in terms of providing cost-effective compound-
target bioactivity predictions. Their main differences lie in the way how the models construct
and treat molecular descriptors, and utilize various learning techniques, including those based
on random forest [16,19,21], kernel learning [15,22,23,32], recommender systems [26], matrix
factorization [20,25,26], Boltzmann machines [27], deep neural networks [16,17], logistic
regression [28], learning to rank [29], and ensemble learning [30,31]. Although such models
have been shown to perform well in cross-validation setups, their practical benefits still remain
largely unknown due to the lack of systematic verification, using targeted experimental assays,
carried out sub-sequent to the prediction phase. In model-guided mapping applications, the
validation experiments are performed based on the model predictions. Such experimental vali-
dation setup effectively avoids any possible information leakage between the training and vali-
dation data, since the validation data does not exist at the time of making the predictions. The
computational-experimental approach, implemented in this study, therefore makes it impossi-
ble to overfit the model to the training data. Here, we used the approach to evaluate the predic-
tive power of a well-established kernel-based learning technique [33]. We chose this model
family since kernel regression approaches have proved good performance in recent computa-
tional studies, including prediction of drug-target interactions [32], peptide-protein binding
affinities [44], drug sensitivities in cancer cell lines [45], as well as in metabolite identification
[46] and QSAR modelling [35].
Taking into account that molecular interactions are not simple on/off relationships, we
focused on a binding affinity prediction problem, using the RLS regression model with a Kro-
necker product kernel (KronRLS). Our systematic evaluation of the predictive performance of
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various descriptors in the form of kernels revealed that their choice has a critical impact on the
prediction accuracy. This is expected because kernel matrix is a central component of the ker-
nel-based learning algorithm as it should capture our prior belief on the relationships between
the input objects. In particular, known binding affinities, even if sparse, constitute an impor-
tant information source not only for model training but also for the kernel matrix construc-
tion. Purely structure-based chemical descriptors were not able to fully capture the changes in
compounds’ activity caused by minor structural differences. Furthermore, we introduced a
novel protein kernel (KP-SW+), based on extended target profile, and showed how it consis-
tently outperformed its commonly-used counterpart, in which the Smith-Waterman amino
acid sequence alignment is adapted exclusively to proteins included in the dataset of interest
(KP-SW). This was evident particularly under the New Target setup (Fig 2C), where the aim is
to predict compounds targeting a new protein not encountered in the training data (correla-
tion of 0.669 for KP-SW+ vs. 0.506 for KP-SW; S7 Fig). Under the same setting, we also
observed a clear advantage of using, for the first time in the context of drug-protein interaction
inference, generic string kernel applied to kinase domains and ATP-binding pockets over full
protein sequences (correlations of 0.651 for KP-GS-domain, 0.628 for KP-GS-atp, 0.508 for
KP-GS; S7 Fig). The majority of kinase inhibitors, including those considered here, bind to
ATP-binding pockets, and short sequences of these pockets are included within the kinase
domain sequences, thus capturing also the neighbouring context. However, polypharmacolo-
gical activities of kinase inhibitors, originating from the conservation of kinase ATP-binding
pockets, make the prediction problem highly challenging, and better accuracies are likely
obtained with compounds having more distinct target profiles. The methodology introduced
here could equally well incorporate other compound and protein classes, such as ion channels
or G-protein-coupled receptors (GPCRs), but further work will be required to investigate its
practical performance under various scenarios using both computational and experimental
validations. For instance, it remains an open question which kernels should be calculated to
best represent such extended pharmacological spaces.
Our results also demonstrate the importance of a proper evaluation procedure of the in sil-
icomodels. A rigorous computational CV protocol is critical to ensure realistic performance
estimates for the optimized models. In particular, the lack of the nested CV strategy in the
model selection may lead to over-optimistic prediction results [32]. It is also important that
CV design reflects the practical application use case of the model. Given a query drug-protein
pair (dx, px), four different prediction scenarios can be distinguished, depending on whether
there exist other compounds with measured bioactivities against px, or proteins with measured
bioactivities against dx (Fig 2 and S1 Table). In turn, different types of CV designs need to be
implemented in order to tune the model parameters and to evaluate its predictive perfor-
mance. Here, we focused on the two most common and practical scenarios of the Bioactivity
Imputation (Fig 2A) and New Drug (Fig 2B). Additionally, we provided the CV results under
the New Target setup (Fig 2C) in S7 Fig. We first adopted LOO-CV, a design that simulates
scattered missing values in otherwise known compound-target bioactivity map, to optimize
the model and asses its performance in filling the experimental gaps (Bioactivity Imputation).
Next, LDO-CV was applied in predicting target interactions for new candidate compounds
having no measured bioactivity data for the model training (New Drug). The latter is much
more challenging task, which was also demonstrated in our results; the correlation between
the measured and predicted binding affinities under the Bioactivity Imputation setup was
much higher (0.829) than under the New Drug scenario (0.653). However, even in the latter
scenario, we still obtained a large number of statistically significant correlation values (S3 Fig).
We further observed a high average AUC values under the Bioactivity Imputation setup (0.945,
S2 Fig), but also under the New Drug prediction scenario (0.853, S2 Fig), which indicates that
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the model is able to discriminate well the interacting from non-interacting compound-kinase
pairs. As expected, the classification accuracy increased with the increasing activity threshold
as the true positive set includes a growing number of most likely interactions.
In practical applications, the method requires features extracted from both compounds and
proteins, such as readily available chemical two-dimensional structures and amino acid
sequences, respectively, based on which kernels can be then calculated. However, if one is
interested in a bioactivity of an investigational drug against a protein with unknown sequence,
a reasonable prediction accuracy can still be achieved if there exist other compounds with mea-
sured bioactivities against a query protein (the New Drug setup). The practical solution is to
replace the protein kernel matrix with an identity matrix, which implies that each protein will
be considered similar to itself only and, effectively, the model will use just known bioactivity
data and drug-drug similarities during both training and prediction phase. In particular, we
noted only a small drop in Pearson correlation after replacing the protein kernel (KP-GS) with
the identity matrix (0.645 vs. 0.653). This observation is expected in multitask or transfer
learning problems, such as the New Drug or New Target setups, where one of the similarities is
essential for generalizing to new instances (drug-drug similarities under the New Drug setting,
protein-protein similarities under the New Target scenario).
Ultimately, even though proper CV design is crucial to tune the model and assess its perfor-
mance, subsequent experimental verification in the laboratory is the only way to really demon-
strate the practical utility of the model predictions for drug discovery applications. The
relatively good agreement between the computationally-predicted and experimentally-mea-
sured bioactivities validated the potential of the kernel-based algorithm, not only for filling the
experimental gaps in existing drug-target interaction maps, but also in later stages of the drug
development process, including prioritizing new target interactions of investigational com-
pounds for further experimental evaluation, hence assisting in understanding of their MoA.
Even though in silico inference of target interactions for new candidate drug compounds is a
highly challenging task, our results with tivozanib suggest that, given enough-representative
and high-quality training data, reliable off-target interaction predictions can be made. In addi-
tion to tivozanib, we initially considered also three other investigational kinase inhibitors,
namely fedratinib, vx11e and ulixertinib (a compound derived from vx11e). However, we
finally selected tivozanib because, unlike for the other compounds, its known on-targets were
placed among the strongest predicted target interactions (S3 Table). This indicates that the pri-
mary on-target space of tivozanib is well-represented in our training data (S8 Fig). In the
future, it is therefore important to profile and build up more diverse training data sets, includ-
ing more examples of compounds targeting different kinase and other target classes.
Tivozanib was originally-developed as a VEGFR inhibitor meant to block angiogenesis by
targeting endothelial cells in the tumor vasculature. However, its MoA has not yet been fully
elucidated. Based on the model predictions, our experimental assay confirmed the two Src
family kinases FRK and FYNA, as well as the non-receptor tyrosine kinase ABL1 and serine/
threonine kinase SLK as tivozanib’s off-targets. Our results highlight that tivozanib has an
unusual target spectrum beyond the VEGFR family of kinases, and this suggests that the best
anti-cancer use of this compound may not be in diseases where other VEGFR inhibitors with
different target profiles have proven effective, but rather in ones where the target spectrum of
tivozanib is more unique. For example, it can be hypothesized that tivozanib may have power-
ful activity in Src-family kinase addicted cancers, where it would target both angiogenesis and
the cancer cells directly. Tivozanib has been shown to have a better safety profile than other
marketed tyrosine kinase inhibitors and, currently, it is undergoing several clinical trials for
the treatment of renal cell carcinoma (NCT03136627), refractory advanced renal cell carci-
noma (NCT02627963), metastatic and non-resectable soft tissue sarcomas (NCT01782313),
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advanced liver cancer (NCT01835223), recurrent ovarian, fallopian tube, or primary perito-
neal cancer (NCT01853644), and advanced prostate cancer (NCT01885949; July 2017). It will
be interesting to see which of these trials will report successful treatment outcomes, and which
will be terminated due to insufficient efficacy or toxicity.
Although presented here results are promising, there is much room for improvement. For
instance, we formulated the predictive model using only one pair of chemical and genomic
descriptors at a time. However, even better accuracies could be obtained with a multiple kernel
learning framework, which integrates multiple biological and molecular data sources, along
with learning their importance for the prediction task [47]. Additional improvement of the
predictive performance could be achieved also by creating more sophisticated kernelized
molecular descriptors, for instance, by comparing three-dimensional structures of protein
binding pockets. Furthermore, we used here as the training data a single yet very comprehen-
sive kinase inhibitor profiling assay containing large number (16,265) of measured com-
pound-kinase binding affinities, spanning different kinase branches (S11 Fig). However, as a
future direction, we plan to work on integrating bioactivity values originating from various
target profiling experiments and bioactivity end-points into a single model [3,19,40,48].
Recently-initiated community-driven efforts, such as Drug Target Commons (https://
drugtargetcommons.fimm.fi), which aim to collectively extract, manage and curate high-qual-
ity compound-target bioactivity data from public databases, literature and other resources, as
well as annotate them with a common ontology, will be essential to facilitate the data standard-
ization and computational modelling purposes. Nevertheless, we hope the current work pro-
vides a useful starting point and a practical guide on how to computationally prioritize the
most promising target interactions for further experimental evaluation.
Materials and methods
Bioactivity dataset
We used publicly available compound-target interaction map generated by Metz et al.using a
large-scale functional bioassay, which measured the concentration of a compound needed to
inhibit the reaction catalysed by a kinase enzyme of interest by 50% [3]. The readout corre-
sponds to an inhibition constant Ki, typically expressed in the logarithmic scale as pKi =
-log10Ki. Although the universal activity threshold cannot be explicitly defined for each com-
pound-kinase pair, the higher the pKi value, the stronger the binding affinity between the com-
pound and kinase.
Among molecules included in the screen, 201 compounds are present in ChEMBL [43],
and 169 proteins belong to the group of catalytically active human protein kinases [37]. The
study is not complete, and therefore we used here a subset of these data: kinases and com-
pounds for which at least 30% of the binding affinity values were measured, resulting in 152
drug compounds and 138 kinase targets. In total, there are 16,265 binding affinities in this
selected interaction map (S9 and S10 Figs). Of note, most of the compounds constitute investi-
gational, not yet FDA-approved, chemical probes.
Prediction model
In supervised learning tasks, training data has the form fðxi; yiÞg
N
i¼1, where N denotes the num-
ber of training examples, xi 2 X is an input object represented as a vector with the feature val-
ues (e.g. a compound represented as a fingerprint vector) and yi 2 Y is its known associated
label value (e.g. a potency of a compound against a certain protein). The aim is to find a predic-
tion function f that models the relationship between xi’s and yi’s, and which can then be used
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to predict the label values for new instances outside the training space. Classical algorithms
search for linear dependencies but often the actual relations underlying the data are highly
nonlinear. Kernels offer the advantage of increasing the power of the linear learning machines
by providing a computationally efficient way of projecting the input data into a high-dimen-
sional feature space. A linear model in this implicit feature space corresponds to a nonlinear
model in the original space. A separation of the statistical learning technique and the data
representation is another convenient attribute of kernels.
Formally, a kernel is a function k that for all x,z 2 X satisfies k(x,z) = hϕ(x),ϕ(z)i, where ϕ is
a mapping from the input space X to an inner product high-dimensional feature space F: ϕ: x
2 X! ϕ(x) 2 F, and it can be considered as a similarity measure between two objects x and z.
It is, however, often possible to avoid the explicit computation of the mapping ϕ, and define
the kernel directly in terms of the original input data items by replacing the inner product h,i
with an appropriately chosen kernel function satisfying certain mathematical properties (so-
called kernel trick). Kernels are particularly handy for calculating similarities between struc-
tured objects, including molecules.
Here, we focused on a regression problem with the objective of predicting real-valued com-
pound-target binding affinities. We used Kronecker regularized least-squares model
(KronRLS) [33,49], a special variant of kernel ridge regression (KRR) which combines linear
least squares with L2-norm regularization (ridge regression) and the kernel trick [50].
In KRR, given a set of N compound-protein pairs as training inputs xi’s, i = 1,. . ., N, and
associated labels yi’s indicating binding affinities between them, we aim to find the minimizer
of the following objective function J:
Jðf Þ ¼
PN
i¼1ðf ðxiÞ   yiÞ
2
þ lkf k2k; ð1Þ
where f indicates the prediction function, f(xi) is the predicted binding affinity of ith com-
pound-protein pair xi, λ denotes a regularisation parameter controlling the balance between
training error and model complexity (λ> 0), and kfkk is a norm of f on the space associated to
kernel function k. In Eq (1), the first term corresponds to the training error, and the second,
controlled by λ, is the penalty term that is larger for complex models that are more likely to
overfit to training data but not generalize well to new instances.
According to the representer theorem [51], the prediction function that minimizes J(f)can
be expressed in terms of linear combination of the training examples:
f ðxÞ ¼
PN
i¼1ai kðxi; xÞ ¼ α
Tk; ð2Þ
where k is a vector with kernel values k(xi,x) between each training point xi and test point x for





j¼1ai aj kðxi; xjÞ: ð3Þ
A vector α, consisting of parameters αi that define the solution to KRR, is found by solving
the following system of linear equations
ðKþ lIÞα ¼ y; ð4Þ
where I is the N×N identity matrix, and y is the vector consisting of labels yi. K denotes N×N
pairwise kernel matrix constructed for all training examples x1, x2,. . ., xN, and thus containing
similarities between all compound-protein pairs. However, the size of K makes the training of
the model computationally very heavy, even for moderate number of compounds and
proteins.
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KronRLS is a special variant of KRR, where one assumes each data point xito consist of two
separate parts, such as compound and protein, each equipped with its own kernel function,
which enables to speed up the model training. Indeed, pairwise kernel K is computed as the









where vec() is the vectorization operator that arranges the columns of a matrix into a vector,
UD and UP are orthogonal matrices with eigenvectors of drug kernel KD and protein kernel
KP, respectively:
KD ¼ UD ΣDU
T
D; ð7Þ
KP ¼ UP ΣPU
T
P ; ð8Þ






Here, SD and SP denote diagonal matrices containing eigenvalues of KD and KP. Label
matrix Y stores binding affinities between nD drug compounds (rows) and nP protein targets
(columns). This way, we completely avoid the computation of the large pairwise kernel K, and
therefore significantly shorten the training time. After applying the well-known property of
the Kronecker product, (A
B)vec(D) = vec(BDAT), the prediction for test point x can be cal-
culated as











Of note, the above shortcuts work only if there are no missing values present in the label
matrix Y. Thus, as the pre-processing step, we imputed the missing binding affinities in Y by
the weighted row (compound) average. The contribution of each protein was weighted by its
similarity (normalized Smith Waterman score) to the protein for which the binding affinity
was missing. Such imputed values were discarded when assessing the predictive performance
of the model.
The implementation of KronRLS is available at https://github.com/aatapa/RLScore. We
tuned the regularization parameter λ of KronRLS algorithm using nested CV (Table 1).
Molecular descriptors
We computed several types of drug compound and protein target molecular descriptors in the
form of kernel matrices KD and KP, respectively. The summary is presented in Fig 3C.
Drug compound space. For drug compounds, we calculated 11 fingerprint-based linear
kernels and Gaussian interaction profile kernel.
Fingerprint encodes a chemical structure into a binary vector, where each bit represents the
presence (1) or absence (0) of the specific substructure in the molecule. We compared two
drug compounds di and dj, represented by their fingerprints, using Tanimoto similarity score,
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Nfpi þ Nfpj   Nfpi ;fpj
; ð11Þ
where fp denotes the fingerprint, Nfpi is the number of 1-bits in the fingerprint fpi of compound
di, and Nfpi,fpj indicates the number of 1-bits in fingerprints of both compounds di and dj. The
idea behind Tanimoto score is based on Jaccard’s index, commonly used for comparing sam-
ple sets. Given a matrix SD of Tanimoto scores between compounds, we computed the finger-




We used the following 11 types of fingerprints calculated using Chemical Structure Cluster-
ing Tool of PubChem [52] (http://pubchem.ncbi.nlm.nih.gov) and rcdk package available for
R [53].
• D-PubChem-2D: 881-bit fingerprint based on two-dimensional substructures defined by
PubChem.
• D-PubChem-3D: PubChem’s descriptor based on up to 10 calculated three-dimensional
conformers of the compound.
• D-PubChem-3D+: PubChem’s descriptor based on up to 10 calculated three-dimensional
conformers of the compound, including additional information (acceptor count, hydro-
phobe count, ring count etc.).
• D-std: 1024-bit path-based, hashed fingerprint.
• D-ext: 1024-bit path-based, hashed fingerprint taking into account ring systems.
• D-graph: 1024-bit path-based, hashed fingerprint considering connectivity.
• D-hybr: 1024-bit path-based, hashed fingerprint considering hybridization states.
• D-sp: 1024-bit fingerprint based on the shortest paths between pairs of atoms taking into
account ring systems and charges.
• D-estate: 79-bit fingerprint corresponding to Estate substructures described by Hall and
Kier [54].
• D-maccs: 166-bit fingerprint based on MACCS structural keys developed by MDL Informa-
tion Systems [55].
• D-kr: 4860-bit fingerprint defined by Klekota and Roth [56].
Furthermore, we defined a feature vector for each drug compound as its quantitative inter-
action profile, i.e. a feature vector vi contains binding affinities (pKi values) between com-
pound di and nP proteins present in our data set, i.e. vi = Yi (ith row of Y). Due to data
sparsity, we first imputed the missing bioactivity values in Y by the weighted row average,
where each row corresponds to binding affinities of a single compound. The contribution of
each protein was weighted by its similarity (normalized Smith Waterman score) to the protein
for which the interaction value was missing. Then, we constructed a Gaussian kernel as
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follows:








where σ is the kernel width.
Protein target space. For kinase targets, we calculated 8 molecular descriptors, i.e. 4 linear
kernels based on comparing protein amino acid sequences and three-dimensional structures,
3 generic string kernels applied to full amino acid sequences, kinase domains and ATP-bind-
ing pockets, as well as Gaussian interaction profile kernel.




where SP is one of the four protein-protein similarity matrices (SP-SW, SP-SW+, SP-3D-energy, SP-
3D-sid), described in the following.
In the first case, we compared protein amino acid sequences using normalized version of
Smith-Waterman (SW) alignment score [57]:









where pi denotes ith protein target, and SW(,) is the original Smith-Waterman score.
Moreover, we introduced a novel molecular descriptor based on extended target profile. In
this case, we derived features for each protein target pi present in our dataset by calculating
normalized SW scores between pi and the bigger set of 20,239 human proteins (hl’s) from the
UniProt database [58] (http://www.uniprot.org/):






Thus, given 138 protein targets in our data set, constructed SP-SW+ matrix has the size of
138 × 20,239. This procedure could be thought of in terms of multiple sequence alignment,
and it allows to derive global protein target features. We used BLOSUM 50 matrix in all the
experiments employing SW alignments.
In order to measure pairwise similarities between three-dimensional protein structures, we
used MISTRAL software, which aligns two proteins based on the minimisation of an energy
function over the low-dimensional space of the relative orientations of the molecules [59]. We
downloaded kinase structures from the Protein Data Bank database [60] (PDB; http://www.
rcsb.org/). PDB files were available for 109 out of 138 kinases in our data set; we retrieved the
structures of the remaining 29 molecules based on their amino acid sequence homology to
proteins present in the PDB database. Then, we calculated SP-3D-energy and SP-3D-sid similarity
matrices relating all pairs of proteins, analogously as in Eq (15) but using obtained from MIS-
TRAL absolute value of the energy needed to align proteins or the sequence identity, respec-
tively, instead of the SW(,) scores. The sequence identity value refers to the number of
aligned amino acids that are of the same chemical type.
We also compared protein targets using generic string (GS) kernel incorporating amino
acid properties [44]. GS kernel compares each substring of protein sequence s of size l L
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with each substring of protein sequence s’ having the same length:
















Here, each comparison results in a score that depends on the shifting contribution term
(difference in the position of two substrings in s and s’, controlled by σp parameter) and the
similarity of amino acids included in two substrings (controlled by σc parameter). The kernel
outputs the sum of the scores from all the substring comparisons.
Vector ψl is constructed as follows. Each type of amino acid am,m = 1,. . .,M, (e.g. Aspara-
gine) has a corresponding feature vector ψ(am) which defines its d properties:
ψðamÞ ¼ ðc1ðamÞ;c2ðamÞ; . . . ;cdðamÞÞ: ð18Þ
Given a protein sequence s = s1, s2,. . ., sl, with all sl 2 S, where S is the set of allM amino
acids, ψl(s) is its encoding function which concatenates l vectors describing each amino acid
the sequence s is composed of:
ψlðsÞ ¼ ðψðs1Þ;ψðs2Þ; . . . ;ψðslÞÞ: ð19Þ
Furthermore, the shifting contribution term gives the GS kernel a useful property of
enabling to match two amino acid subsequences even if their positions in the full protein
sequences differ notably.
We used BLOSUM 50 matrix as amino acid descriptors, and we calculated three GS kernels
based on comparing full protein kinase sequences, as well as sequences of kinase domains and
ATP-binding pockets retrieved from the PROSITE database [61] (http://prosite.expasy.org/).
Finally, we calculated Gaussian protein interaction profile kernel as:








The formulation above is analogous to the compound interaction profile kernel defined in
Eq (13), but now feature vector denoted by wi contains binding affinities between protein pi
and all compounds present in our data set. All the kernel matrices are positive semidefinite
and were normalized. Kernel parameters were tuned using nested cross-validation.
Model evaluation procedure
We used nested cross-validation (CV) procedure for model selection, and we assessed the pre-
dictive power with Pearson correlation and root mean squared error (RMSE) between original
and predicted pKi values.
In k-fold CV, the dataset is randomly divided into k subsamples of equal size, and the
model is trained based on k-1 of them (training data). Then, the remaining subsample (test
data) is used to assess how well the model that has been found generalizes to new instances, i.e.
to calculate the predictive performance. The procedure is repeated k times, such that each sub-
sample is used once as the test data, and the average error over the k folds gives the final
estimate.
Nested CV consists of two loops, outer and inner one. In the outer CV loop, each of the k
folds is kept as a test set at a time. The remaining k-1 training folds of the outer CV loop are
further divided into training and test set of the inner CV loop. Here, the inner CV was per-
formed during each round of the outer CV, with the aim of selecting the regularization
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parameter λ of KronRLS algorithm as well as kernel parameters (S4 Table). We performed a
grid search in order to select the most suitable combination of all parameters. Then, training
folds of the outer CV loop were used to train the model with selected parameters, and the pre-
dictive performance was evaluated on the test set.
We applied two different CV strategies, i.e. leave-one-out nested cross-validation
(LOO-CV) and leave-drug-out nested cross-validation (LDO-CV), summarized in Table 1
and S12 and S13 Figs.
We note that it is critical to discard binding affinities of compound-protein pairs belonging
to the test fold of both inner and outer CV prior to computing Gaussian interaction profile
kernels (KD-GIP, KP-GIP) in order to avoid significant model overfitting. Here, we used
interaction profile kernels with LOO-CV, and we removed from the compound-protein inter-
action matrix Y the whole column (row) containing the test point before computing KD-GIP
(KP-GIP) kernel.
Kinase assays
Testing bioactivities predicted to fill the experimental gaps. We used Kinase Selectivity
Profiling System + ADP-Glo Assay kits (Promega, TK-1 V6851, TK-2 V6853, TK-3 V6921) for
performing kinase selectivity profiling at 1uL reaction volume on 1536-well assay plates (Corn-
ing, #3937). The reagents were prepared as indicated in Promega technical manual (TM421),
and transferred to Echo Qualified 384-Well Polypropylene Microplate source plates (Labcyte,
P-05525). We pre-plated five kinase inhibitors tested (cediranib, lapatinib, gefitinib, vx-745,
pazopanib; all dissolved in DMSO; S5 Table) at 12 concentrations (12500, 3750, 1250, 375,
125, 37.5, 12.5, 3.75, 1.25, 0.375, 0.125, 0.0375 nM) on the 1536-well white round bottom assay
plates using acoustic dispenser (Labcyte, ECHO550 Liquid handler) and DMSO transfer cali-
bration. The inhibitors were transferred at 7.5 and 2.5 nL volumes from Echo Qualified
384-Well Low Dead Volume Microplates (Labcyte, LP-0200).
The kinase inhibitors were dissolved to 1X Kinase Buffer with 5% DMSO by transferring
200nL of the buffer using ECHO525 Liquid handler (Labcyte). After the transfer, the assay
plate was immediately sealed to minimize evaporation, and centrifuged at 872rcf/2min/RT.
The dissolved kinases and 2.5X kinase buffer controls were transferred at 400nL using
ECHO525. Plates were sealed, centrifuged at 872rcf/2min/RT, mixed with plate shaker for 2
minutes and incubated 10min/RT plate upside down. The 2.5X ATP/substrate working stocks
were transferred at 400nL using ECHO525. Plates were sealed, centrifuged at 872rcf/2min/RT,
mixed with plate shaker for 2 minutes, and incubated upside down (60min/RT).
For the ADP detection, 1 μl ADP-Glo reagent was dispensed (Thermo Scientific Multidrop
Combi nL). Plates were sealed, centrifuged at 872rcf/2min/RT, mixed with plate shaker for 2
minutes and incubated upside down (40 min/RT). Next, 2 μl kinase detection reagent was dis-
pensed with Thermo Scientific Multidrop Combi nL. Plates were sealed, centrifuged at 872rcf/
2min/RT, mixed with plate shaker for 2 minutes and incubated upside down (30min/RT).
Luminescence (0.5sec/well) was measured using PheraSTAR (BMG LABTECH) and
1536-plate compatible spoon.
The Kinase Selectivity Profiling System kit assays were performed at least in two individual
experiments, each having two replicates.
Testing predicted targets for a kinase inhibitor tivozanib. For tivozanib’s off-target test-
ing, ABL1, RPS6KB, SLK, Aurora A, HIPK4, FYN A, FRK, as well as their substrates and buff-
ers were purchased from SignalChem (product codes and assay concentrations available in S6
Table). Kinase assay, kinase dilution and substrate buffers were as indicated by the manufac-
turer (Promega). The assays were performed in the same way as with the kinases from the
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Kinase Selectivity Profiling System + ADP-Glo Assay kits (see previous section). All the assays
were done in three individual experiments, each having three replicates.
Analysis of the kinase assay results. IC50 values from all the experiments were obtained
with GraphPad Prism 7 (GraphPad Software, Inc. California, USA) using inhibitor vs. response—
variable slope (four parameters) analysis. Constrain bottom was set tomust be between zero and
100, and constrain hill slope was set to absolute value must be less than 1.5. X-axis scale was set to
log10. Sigmoidal dose-response curves are shown in S14 and S15 Figs.
Supporting information
S1 Fig. (a) Leave-one-out and (b) leave-drug-out cross-validation results. The prediction
accuracy was assessed with root mean squared error (RMSE) between binding affinities (pKi)
from the study by Metz et al. and those predicted using KronRLS model with different pairs of
drug (rows) and protein (columns) molecular descriptors encoded as kernel matrices (c). The
lower the RMSE value, the more accurate the model prediction. Of note, Gaussian interaction
profile drug kernel (KD-GIP) which resulted in the highest predictive performance under the
Bioactivity Imputation scenario (a) has not been evaluated under the New Drug setup (b)
because it is constructed based on the bioactivity profile of a drug, information that in practice
is unavailable when predicting target interactions for a new investigational drug compound.
(PDF)
S2 Fig. (a,b) Scatter plots between compound-kinase binding affinities (pKi) measured in
the Metz et al. study and their model predictions under the (a) Bioactivity Imputation, (b)
New Drug setups, using KronRLS algorithm with the best pairs of drug and protein ker-
nels. r indicates Pearson correlation and p-values were calculated using a Student’s t distribu-
tion for a transformation of the correlation, as implemented in MATLAB Statistics Toolbox.
Each point corresponds to one of 16,265 compound-kinase pairs. Most of the assays were per-
formed at the inhibitor concentrations of 3–10,000 nM (corresponding to minimum pKi of 5
M); however, some affinities were larger than 10,000 nM explaining the few outlier points with
pKi < 5 M. The higher the pKi value, the stronger the affinity between the two molecules. Red
lines mark a relatively stringent interaction threshold (7 M), distinguishing the top left corner
as the region containing false positive interaction predictions, and the bottom right corner as
false negative predictions. (c,d) Receiver operating characteristic (ROC) curves constructed
under the (c) Bioactivity Imputation and (d) New Drug setups using 21 different interaction
threshold values (pKi varying between 6 and 8 M with a step of 0.1 M) to binarize binding
affinities measured in the Metz et al. study into true class labels. Multiple values were used
to study the ability of the model to discriminate interacting from non-interacting compound-
kinase pairs at various interaction thresholds. The curves corresponding to the threshold of
pKi = 7 M, marked at the scatter plots (a) and (b), are plotted with the darkest red colour. AUC
indicates the area under the ROC curve; the closer AUC is to 1, the more accurate the model
prediction.
(PDF)
S3 Fig. Distribution of 152 drug-wise Pearson correlation values between compound-
kinase binding affinities (pKi) measured in the Metz et al. study and their model predic-
tions under the New Drug scenario. The predictions were made using KronRLS algorithm
with the best pair of drug and protein kernels (KD-sp and KP-GS) under the leave-drug-out
cross-validation. 125 out of 152 correlations are statistically significant (p< 0.0001), and 58
correlation values are greater than 0.75.
(PDF)
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S4 Fig. Scatter plots between the measured compound-kinase binding affinities from Metz
et al. study and their model predictions obtained using KronRLS with KD-GIP drug kernel
and KP-GS-domain protein kernel. r indicates Pearson correlation and p-values were calcu-
lated using a Student’s t distribution for a transformation of the correlation, as implemented in
MATLAB Statistics Toolbox. Each plot corresponds to a single compound selected for the
experimental validation, and each point represents its bioactivity against a single kinase. Points
marked with red stars and orange dots are predictions for the unmeasured in Metz et al. study
compound-kinase pairs; thus, they are placed on the y-axis. Red star-shapes and green triangu-
lar points indicate interactions included in our experimental validation. However, the green
points constitute merely an experimental control as those binding affinities are reported in
Metz et al. data set. The higher the pKi value, the stronger the affinity between the two mole-
cules. Red lines mark a pre-defined interaction threshold (7 M), distinguishing top left corner
as the region containing false positive (FPs) interaction predictions, and bottom right corner
as false negative (FN) predictions. During the selection of the molecules for the experimental
validation, we aimed at minimizing the number of FPs and FNs. For instance, in case of cedir-
anib (a), there are no FPs, meaning that the predicted interaction, indicated by the red star, is
likely a true one. The percentage of missing values indicates unmeasured binding affinities of a
given compound against a set of 138 kinases in the Metz et al. data set.
(PDF)
S5 Fig. The comparison between model-predicted and experimentally-measured in differ-
ent assays bioactivities of 100 compound-kinase pairs included in our experimental valida-
tion. (a,c) Technical variability between two experimental kinase assays. Scatter plots between
(a) 82 pKi values measured in Metz et al. study and pIC50 values from our experimental assay;
(c) 95 pKd values from Davis et al. study and pIC50 values from our experimental assay; (b) 73
in silico-predicted and measured in Metz et al. study pKi values, excluding compound-kinase
pairs blinded in the model training (marked with orange colour in Fig 4A and S2 Table); (d)
95 in silico-predicted pKi values and pKd readouts from Davis et al. study. The values are
detailed in S2 Table.
(PDF)
S6 Fig. The comparison between model-predicted (based on the data from Metz et al.
study) and experimentally-measured (in the study by Davis et al.) compound-kinase bioac-
tivities. (a) The Bioactivity Imputation scenario. The KronRLS model was trained usingMetz
et al. dataset together with the best-performing (under the Bioactivity Imputation scenario)
drug interaction profile kernel (KD-GIP) and kinase domain-based generic string protein ker-
nel (KP-GS-domain, Fig 3A). The model was then used to predict binding affinities between
2,662 compound-kinase pairs overlapping between Metz et al. and Davis et al. datasets. (b)
The New Target scenario. The KronRLS algorithm was trained usingMetz et al. dataset
together with the best-performing (under the New Target scenario) PubChem’s fingerprint-
based drug kernel (KD-PubChem-2D) and extended target profile protein kernel built upon
Smith-Waterman amino acid sequence comparisons (KP-SW+, S7 Fig). The model was then
used to predict the binding affinities between 152 drugs from Metz et al. study and 244 wild-
type kinases present in Davis et al. but not Metz et al. dataset. The predictive performance was
evaluated based on 5,368 binding affinities of 22 drugs overlapping between the two datasets.
(PDF)
S7 Fig. (a) Leave-target-out cross-validation results. The prediction accuracy was evaluated
with Pearson correlation (r) between binding affinities (pKi) from the study by Metz et al. and
those predicted using KronRLS algorithm with different pairs of drug (rows) and protein
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(columns) molecular descriptors encoded as kernel matrices (b).
(PDF)
S8 Fig. Kinase dendrogram created by hierarchical clustering of 138 kinases from Metz
et al. study based on their bioactivity data (pKi). The bar length is proportional to the num-
ber of compound interactions for each kinase (pKi 7 M). On-targets of tivozanib are marked
with red lines (FLT1, FLT4, KDR), fedratinib–green lines (JAK2, JAK3, TYK2), vx11e and
ulixertinib (a compound derived from vx11e)–blue lines (vx11e: CDK2, ERK2; ulixertinib:
ERK2).
(PDF)
S9 Fig. Interaction map between 152 compounds (rows) and 138 kinases (columns) pro-
filed in the study of Metz et al. The white cells represent unmeasured binding affinities. The
higher the pKi value, the stronger the affinity between the compound and kinase.
(PDF)
S10 Fig. Distribution of 16,265 compound-kinase binding affinities measured in the study
of Metz et al.
(PDF)
S11 Fig. Kinome map of 138 kinases used in our work. Figure was created with KinMap
(http://kinhub.org/kinmap).
(PDF)
S12 Fig. Schematic illustration of the nested leave-one-out cross-validation (LOO-CV)
procedure, consisting of the inner loop for model selection, and the outer loop for model
performance estimation. Single round of the outer CV is shown, where one compound-pro-
tein pair is removed from the training data, and used as a test fold. The inner leave-one-out
CV is run for each model parameter combination (grid search) during every round of the
outer CV. The combination resulting in the lowest root mean squared error between the origi-
nal and predicted binding affinities is selected and used in the model training in the outer CV
loop. We used LOO-CV to tune the model parameters and assess its performance under the
Bioactivity Imputation scenario (Fig 2A).
(PDF)
S13 Fig. Schematic illustration of the nested leave-drug-out cross-validation (LDO-CV)
procedure consisting of the inner loop for model selection, and the outer loop for model
performance estimation. Single round of the outer CV is shown, where all binding affinities
of selected compound are removed from the training data, and used as a test fold. The inner
leave-drug-out CV is run for each model parameter combination (grid search) during every
round of the outer CV. In the inner CV, five compounds are removed at a time (at random).
The model parameter combination resulting in the lowest root mean squared error between
the original and predicted binding affinities is selected and used in the model training in the
outer CV loop. Note that also the rows and columns corresponding to the compounds
included in the test fold are removed from the drug kernel matrix before model training. We
used LDO-CV to tune the model parameters and assess its performance under the New Drug
scenario (Fig 2B).
(PDF)
S14 Fig. Results of our kinase assay for testing bioactivities predicted to fill the experimen-
tal gaps in the large-scale kinase inhibitor target profiling study by Metz et al.; examples of
drug response curves obtained as described in Materials and Methods section of the main
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paper. Corresponding pIC50 values are summarized in S2 Table.
(PDF)
S15 Fig. Results of our kinase assay for testing predicted target interactions for a new
investigational kinase inhibitor tivozanib; drug response curves obtained as described in
Materials and Methods section of the main paper. Corresponding pIC50 values are summa-
rized in S3 Table.
(PDF)
S16 Fig. Visualisation of the binding between tivozanib and ABL1 (PDB code: 2e2b). The
docking was performed with Rosetta (https://www.rosettacommons.org/) and the figure was
created using UCSF cHimera (https://www.cgl.ucsf.edu/chimera/). A radius for docking was
set to 5 Å around the centre of the ATP-binding site.
(PNG)
S1 Table. Possible drug-protein interaction prediction scenarios. In this work, we focused
on two most practical ones, namely the Bioactivity Imputation (Fig 2A) and the New Drug (Fig
2B) scenarios. Additionally, we included the results under the New Target setup (Fig 2C) in S7
Fig. (dx, px) denotes the query drug-protein pair, the binding affinity of which one aims to pre-
dict.
(PDF)
S2 Table. Results of the experimental validation of bioactivities predicted to fill the gaps in
the study of Metz et al.
(XLSX)
S3 Table. Predicted target profile of tivozanib and the results of experimental validation.
(XLSX)
S4 Table. Model parameters tested. In case of Gaussian kernels (KD-GIP, KP-GIP), the values
for kernel width parameter σ were selected by computing pairwise distances between all data
points and taking 0.1, 0.5 and 0.9 quantiles.
(PDF)
S5 Table. Kinase inhibitors used in our experimental assays.
(PDF)




The authors would like to thank Dr. Lari Lehtiö for careful reading and expert comments on
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